Biochemical effects of piceatannol in human HL-60 promyelocytic leukemia cells - Synergism with Ara-C

International Journal of Oncology

Volumn 33, Issue 4, 2008, Pages 887-892

  Fritzer Szekeres, Monika ^a   Savinc, Ivo ^a   Horvath, Zsuzsanna ^a   Saiko, Philipp ^a   Pemberger, Michael ^a   Graser, Geraldine ^a   Bernhaus, Astrid ^a   Ozsvar Kozma, Maria ^a   Grusch, Michael ^a   Jaeger, Walter ^b   Szekeres, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Ara C; Leukemia; Piceatannol; Resveratrol; Ribonucleotide reductase

Indexed keywords

CARBON 14; CYTARABINE; CYTIDINE; DEOXYCYTIDINE TRIPHOSPHATE; DEOXYGUANOSINE TRIPHOSPHATE; DNA; PICEATANNOL;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN HL 60; CHEMICAL ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DEPLETION; STRUCTURE ACTIVITY RELATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL CYCLE; CYTARABINE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MODELS, CHEMICAL; PROPIDIUM; RIBONUCLEOTIDE REDUCTASES; STILBENES; TIME FACTORS;

EID: 54049100364     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000077     Document Type: Article

References (33)

1. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA and Burke MD: The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774-778, 2002.
2. Renaud S and de Lorgeril M: Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526, 1992.
3. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu. S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B and Sinclair DA: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196, 2003.
4. Goldberg DM, Yan J and Soleas GJ: Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36: 79-87, 2003.
5. Wolter F, Clausnitzer A, Akoglu B and Stein J: Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J Nutr 132: 298-302, 2002.
6. Hung LM, Chen JK, Lee RS, Liang HC and Su MJ: Beneficial effects of astringinin, a resveratrol analogue, on the ischemia and reperfusion damage in rat heart. Free Radic Biol Med 30: 877-883, 2001.
7. Murias M, Jager W, Handler N, Erker T, Horvath Z, Szekeres T, Nohl H and Gille L: Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol 69: 903-912, 2005.
8. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M and Aggarwal BB: Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 102: 987-995, 2003.
9. Richard N, Porath D, Radspieler A and Schwager J: Effects of resveratrol, piceatannol, tri-acetoxystilbene, and genistein on the inflammatory response of human peripheral blood leukocytes. Mol Nutr Food Res 49: 431-442, 2005.
10. Larrosa M, Tomas-Barberan FA and Espin JC: The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr 43: 275-284, 2004.
11. Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze-Osthoff K, Dorken B, Schmalz HG, Daniel PT and Henze G: Piceatannol, a hydroxylated analog of the chemo-preventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 15: 1735-1742, 2001.
12. Tolomeo M, Grimaudo S, Di Cristina A, Roberti M, Pizzirani D, Meli M, Dusonchet L, Gebbia N, Abbadessa V, Crosta L, Barucchello R, Grisolia G, Invidiata F and Simoni D: Pterostilbene and 3′-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. Int J Biochem Cell Biol 37: 1709-1726, 2005.
13. Geahlen RL and McLaughlin JL: Piceatannol (3,4,3′,5′-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 165: 241-245, 1989.
14. Palmieri L, Mameli M and Ronca G: Effect of resveratrol and some other natural compounds on tyrosine kinase activity and on cytolysis. Drugs Exp Clin Res 25: 79-85, 1999.
15. Mishra NC, Sharma M and Sharma A: Inhibitory effect of piceatannol, a protein tyrosine kinase inhibitor, on asexual maturation of Plasmodium falciparum. Indian J Exp Biol 37: 418-420, 1999.
16. Su L and David M: Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. J Biol Chem 275: 12661-12666, 2000.
17. Balaian L, Zhong RK and Ball ED: The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression. Exp Hematol 31: 363-371, 2003.
18. Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, Weiss A and Kipps TJ: ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 105: 2036-2041, 2005.
19. Fontecave M, Lepoivre M, Elleingand E, Gerez C and Guittet O: Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 421: 277-279, 1998.
20. Elford HL, Freese M, Passamani E and Morris HP: Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem 245: 5228-5233, 1970.
21. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W: Inhibition of ribonucleotide reduction in CCRF- CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38: 567-572, 1990.
22. Gandhi V and Plunkett W: Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41: 93-103, 2002.
23. Fritzer-Szekeres M, Salamon A, Grusch M, Horvath Z, Hochtl T, Steinbrugger R, Jager W, Krupitza G, Elford HL and Szekeres T: Trimidox, an inhibitor of ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 64: 481-485, 2002.
24. Garrett C and Santi DV: A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem 99: 268-273, 1979.
25. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
26. Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T and Jager W: Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 12: 5571-5578, 2004.
27. Wung BS, Hsu MC, Wu CC and Hsieh CW: Piceatannol upregulates endothelial heme oxygenase-1 expression via novel protein kinase C and tyrosine kinase pathways. Pharmacol Res 53: 113-122, 2006.
28. Islam S, Hassan F, Mu MM, Ito H, Koide N, Mori I, Yoshida T and Yokochi T: Piceatannol prevents lipopolysaccharide (LPS)-induced nitric oxide (NO) production and nuclear factor (NF)-kappaB activation by inhibiting IkappaB kinase (IKK). Microbiol Immunol 48: 729-736, 2004.
29. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S and Aggarwal BB: Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J Immunol 169: 6490-6497, 2002.
30. Nakamura N and Wada Y: Properties of DNA fragmentation activity generated by ATP depletion. Cell Death Differ 7: 477-484, 2000.
31. Ferrigni NR, McLaughlin JL, Powell RG and Smith CR Jr: Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J Nat Prod 47: 347-352, 1984.
32. Nuckel H, Rebmann V, Durig J, Duhrsen U and Grosse-Wilde H: HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105: 1694-1698, 2005.
33. Hamblin TJ: Predicting Progression - ZAP-70 in CLL. N Engl J Med 351: 856-857, 2004.